一种天然的PCID2-向性化合物抑制肝细胞癌的进展:基于结构的发现和生物评估的证据
Zebanuer Yuemaierjiang1, Jingjing Sun1,2, Jiamin Song1
1The First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu, China.
Frontiers in pharmacology
|December 15, 2025
概括
1,2,3,4,6-Penta-O-galloyl-β-D-glucose (β-PGG) 是一种天然化合物,在肝细胞癌 (HCC) 中有效向PCID2. β-PGG抑制HCC细胞的生长和迁移,为肝癌治疗提供了一个有前途的新途径.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
背景情况:
- 肝细胞癌 (HCC) 是一种致命的癌症,治疗选择很少.
- PCID2 (PCI-domain含蛋白2) 是HCC的潜在治疗点,但缺乏特定的抑制剂.
- 传统中医 (TCM) 提供了丰富的新型抗癌化合物的来源.
研究的目的:
- 为了识别针对PCID2的新型小分子,用于HCC治疗.
- 为了研究1,2,3,4,6-Penta-O-galloyl-β-D-葡萄糖 (β-PGG) 对HCC的抗癌作用和机制.
主要方法:
- 分子对接被用来选TCM衍生化合物用于PCID2向.
- 表面等离子体共振 (SPR) 验证了β-PGG与PCID2.2的结合.
- 在体外测试中评估了β-PGG对HCC细胞增殖,迁移,入侵,细胞亡和细胞循环的影响,用于机制探索使用了西方涂抹.
主要成果:
- 分子对接确定β-PGG是一种强大的PCID2抑制剂;SPR证实了直接结合.
- β-PGG显著抑制了HCC细胞的增殖,迁移和入侵.
- β-PGG诱导的亡和细胞循环停止,降低PCID2,循环D1,CDK6的调节,并抑制PI3K/Akt酸化.
结论:
- 通过向PCID2和调节关键信号通路,β-PGG表现出显著的抗HCC活性.
- β-PGG是HCC治疗的有希望的化合物,验证了PCID2作为治疗点.
- 这项研究强调了TCM衍生化合物的潜力,以发现新的肝癌治疗方法.
关键词:
1,2,3,4,6-penta-O-galloyl-β-D-glucose (β-PGG) 是一种葡萄糖,它可以分为两种类型.包含蛋白质2 (PCID2) 的PCI领域.肝细胞癌 (HCC) 是一种肝细胞癌.抑制的增殖抑制的增殖.虚拟查 (VS) 是指虚拟的查.更多相关视频
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
2.6K
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
9.4K
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K